Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 3Recurrence 2Lymphoproliferative Disorders 2Burkitt Lymphoma 2Neoplasms 1Neoplasm, Residual 1Lymphatic Diseases 1Immunoproliferative Disorders 1

Interventions

blinatumomab 3Cytarabine 3venetoclax 2revumenib 2Daunorubicin 2quizartinib 1obinutuzumab 1nilotinib 1ivosidenib 1etoposide phosphate 1bosutinib 1acalabrutinib 1Mitoxantrone 1Midazolam 1Itraconazole 1Imatinib Mesylate 1Idarubicin 1Gemtuzumab 1Etoposide 1Drug Therapy 1Cobicistat 1Azacitidine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × Leukemia × blinatumomab × Clear all
NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Amgen

Phase 2 Completed
45 enrolled 24 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Terminated
405 enrolled 27 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207388 2020-02-10

BLAST

Amgen Research (Munich) GmbH

Phase 2 Completed
116 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡